EBIT at other companies
Other financials
Where this comes from
Calculated from Spyre Therapeutics, Inc.’s reported figures.
Plus components not separately reported this period.
The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Spyre Therapeutics, Inc.'s ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Spyre Therapeutics, Inc.'s EBIT?
- Spyre Therapeutics, Inc. (SYRE) reported EBIT of -$45.64M in Q1 2026.
- How has Spyre Therapeutics, Inc.'s EBIT changed year-over-year?
- Spyre Therapeutics, Inc.'s EBIT increased by 14.8% year-over-year, from -$53.57M to -$45.64M.
- What is the long-term trend for Spyre Therapeutics, Inc.'s EBIT?
- Over 4 years (2021 to 2025), Spyre Therapeutics, Inc.'s EBIT has grown at a 33.7% compound annual growth rate (CAGR), from -$65.65M to -$209.56M.
- What does EBIT mean?
- Profit before interest and taxes — the business's core earning power.
- How do you interpret EBIT?
- Higher is better. Because it adds back interest, EBIT compares earning power across firms with very different debt loads — the base for interest coverage and the EV/EBIT multiple. For filers reporting operating income it equals that line, excluding non-operating swings.
- How does EBIT compare across companies?
- Comparable across companies regardless of leverage or tax domicile; the standard 'earning power' line for cross-company analysis. Least meaningful for banks and insurers.